ReviewChirurgie (Heidelberg, Germany)2026
[Personalized systemic treatment of metastatic esophageal cancer].
Review in Chirurgie (Heidelberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The systemic treatment landscape of metastatic esophageal cancer has changed over the past decade. For a long time, platinum-based chemotherapy combinations were the only standard option but now immune checkpoint inhibitors, administered either as monotherapy or in combination with chemotherapy, enable a significantly improved overall survival in selected patients. Prerequisites for appropriate treatment selection are precise histological and molecular classifications of the tumor. In esophageal squamous cell carcinoma, histology and programmed cell death ligand 1 (PD-L1) expression are the principal determinants of first-line treatment. The use of different PD-L1 scoring systems in pivotal clinical trials complicates the application in routine practice. For esophageal adenocarcinoma palliative systemic treatment largely follows contemporary treatment algorithms for metastatic gastric and gastroesophageal junction cancer, incorporating the HER2, Claudin18.2, MSI/MMR and PD-L1 status. This review summarizes the current evidence, focusing on metastatic esophageal squamous cell carcinoma and provides practical recommendations for multidisciplinary patient management.
Indexed as
Identifiers
42616054What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.